肝胆胰外科杂志

• 论文 • 上一篇    下一篇

经肝动脉化疗栓塞联合射频消融术对中晚期原发性肝癌的近期疗效分析

匡远黎, 王郑, 杨志亮, 谭智明   

  1. 重庆开州区人民医院 肝胆心胸外科,重庆 405400
  • 收稿日期:2017-04-04 出版日期:2017-07-05 发布日期:2017-07-05
  • 通讯作者: 谭智明,主任医师,E-mail:tzm18374411@163.com。
  • 作者简介:匡远黎(1988-),男,重庆人,主治医师,硕士。

Therapeutic effects of transcatheter arterial chemoembolization combined with radiofrequency ablation in the treatment of advanced primary hepatocellular carcinoma

KUANG Yuan-li, WANG Zheng, YANG Zhi-liang, TAN Zhi-ming   

  1. Department of Hepatobiliary Cardiothoracic Surgery, The People's Hospital of Kaizhou District, Chongqing 405400, China
  • Received:2017-04-04 Online:2017-07-05 Published:2017-07-05

摘要: 目的 探讨经肝动脉化疗栓塞(TACE)联合经皮肝穿刺射频消融术(RFA)治疗中晚期原发性肝癌(PHC)的临床疗效和安全性。方法 将125例中晚期PHC患者按治疗方法不同分为TACE组(40例)、RFA组(38例)及TACE+RFA组(47例),观察3组近期疗效和并发症发生情况;采用Kaplan-Meier法计算复发率、生存率及中位生存期,比较采用Log-Rank时序检验。结果 TACE+RFA组总有效率为74.5%,明显高于TACE组的52.5%和RFA组的47.4%(P<0.05);TACE+RFA组1、2年复发率分别为17.0%、31.9%,均明显低于TACE组(37.5%、57.5%)和RFA组(42.1%、60.5%)(P<0.05);TACE+RFA组1、2年生存率分别为89.4%、70.2%,均明显高于TACE组(70.0%、47.5%)和RFA组(68.4%、44.7%)(P<0.05);且TACE+RFA组中位生存期(26个月)明显长于TACE组(21个月)和RFA组(19个月)(P<0.05)。结论 TACE联合RFA可有效治疗中晚期PHC,减少术后复发率并提高生存率,延长患者生存期,其疗效优于单纯TACE或单纯RFA治疗。

关键词: 原发性肝癌, 肝动脉化疗栓塞, 射频消融术, 介入治疗, 疗效

Abstract: Objective To investigate the therapeutic effects and safety of transcatheter arterial chemoembolization (TACE) combined with percutaneous radiofrequency ablation (RFA) in the treatment of advanced primary hepatocellular carcinoma (PHC). Methods A total of 125 cases of patients with advanced PHC were divided into the TACE group (n=40), RFA group (n=38) and TACE+RFA group (n=47) according to the different therapeutic methods. The short-term efficacy and complications of the 3 groups were observed. The recurrent rate, survival rate and median survival time (MST) were calculated by Kaplan-Meier method, and the differences of them between the three groups were analyzed by Log-Rank test. Results The total effective rate of the TACE+RFA group was 74.5%, which was obviously higher than that of the TACE group (52.5%) and that of the RFA group (47.4%) (P < 0.05). The 1- and 2-year recurrent rates of the TACE+RFA group were 17.0% and 31.9%, respectively, which were both significantly lower than those of the TACE group (37.5% and 57.5%) and those of the RFA group (42.1% and 60.5%) (P<0.05). Moreover, the 1- and 2-year survival rates of the TACE+RFA group were 89.4% and 70.2%, respectively, which were both evidently higher than those of the TACE group (70.0% and 47.5%) and those of the RFA group (68.4% and 44.7%) (P<0.05). Additionally, the MST of the TACE+RFA group (26 months) was observably longer than that of the TACE group (21 months) and that of the RFA group (19 months) (P<0.05). Conclusion The therapy of TACE combined with RFA could improve the survival rate and prolong the survival time of advanced PHC patients. And it has a better therapeutic effect on advanced PHC than that of single TACE or single RFA.

Key words: primary hepatocellular carcinoma, transcatheter arterial chemoembolization, radio frequency ablation, interventional therapy, therapeutic effect

[1] FORNER A, LLOVET JM, BRUIX J. Hepatocellular carcinoma [J]. Lancet, 2012, 379(9822): 1245-1255.
[2] CABRERA R, NELSON D R. Review article: the management of hepatocellular carcinoma [J]. Aliment Pharmacol Ther, 2010, 31(4): 461-476.
[3] SCHLACHTERMAN A, JR C W, HILGENFELDT E, et al. Current and future treatments for hepatocellular carcinoma [J]. World J Gastroenterol, 2015, 21(28): 8478-8491.
[4] 杨家进, 吴建兵. 原发性肝癌综合介入治疗进展[J]. 实用肝脏病杂志, 2015, 18(2): 118-119.
[5] 黄优华, 徐强, 沈涛, 等. 肝动脉化疗栓塞联合射频消融治疗中晚期肝癌的疗效评价[J]. 海南医学, 2013, 24(24): 3630-3632.
[6] 徐丽丽, 李春晖, 张冰. 超声引导下射频消融联合TACE治疗进展期原发性肝癌疗效及并发症分析[J]. 贵州医药, 2016, 40(3): 265-267.
[7] 梁宏元, 卢再鸣. 原发性肝癌综合介入治疗现状与困惑[J]. 临床肝胆病杂志, 2016, 32(1): 44-48.
[8] 陈中, 倪家连, 刘鲁岳. 手术切除治疗巨大原发性肝癌的预后因素分析[J]. 中华肿瘤杂志, 2011, 33(9): 710-713.
[9] 张俊雅, 温晓斐, 闫鹏, 等. 原发性肝癌的介入治疗现状与进展[J]. 现代生物医学进展, 2016, 16(29): 5797-5800.
[10] 吕天石,邹英华,王健, 等. 经肝动脉化疗栓塞术联合射频消融治疗原发性肝癌的现状[J]. 临床肝胆病杂志, 2016, 32(1): 49-55.
[11] 钟嘉明, 刘丽, 陈晓霞, 等. 肝外动脉供血在原发性肝癌介入治疗中的意义[J]. 临床和实验医学杂志, 2016, 15(11): 1083-1086.
[12] MURATA S, MINE T, UEDA T, et al. Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma [J]. Sci World J, 2013, 2013(2): 479805.
[13] HUCKE F, SIEGHART W, PINTER M, et al. The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE [J]. J Hepatol, 2014, 61(1): 118-126.
[14] SIEGHART W, HUCKE F, PINTER M, et al. 102 ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma[J]. Hepatol, 2013, 57(6): 2261-2273.
[15] IKEDA K, OSAKI Y, NAKANISHI H, et al. Recent progress in radiofrequency ablation therapy for hepatocellular carcinoma [J]. Oncol, 2014, 87( Suppl 1): 73.
[16] 蔡烈, 李志伟, 王元喜. 原发性肝癌的手术切除及介入治疗分析[J]. 医学综述, 2015, 21(6): 1121-1123.
[17] 王法. 肝动脉化疗栓塞术联合射频消融术治疗小肝癌的研究进展[J]. 实用肿瘤学杂志, 2013, 27(5): 447-451.
[18] 严翔, 付必莽, 唐波, 等. 射频消融术治疗原发性肝癌的临床研究进展[J]. 肝胆胰外科杂志, 2016, 28(1): 87-88.
[19] 施昌盛, 杨庆, 乔彬彬, 等. 射频消融对TACE术后残余病灶的疗效分析[J]. 介入放射学杂志, 2016, 25(12): 1097-1100.
[1] 黄帆, 吴若林, 陈广厚, 郑可中, 方皓舒, 王国斌, 赵红川.
公民逝世后器官捐献老年供肝肝移植短期疗效单中心分析
[J]. 肝胆胰外科杂志, 2023, 35(9): 525-529,535.
[2] 丁兢, 邸亮, 李聪, 赵晓飞, 郭庆良, 马超. 术前血清VEGF和IL-12水平对原发性肝癌腹腔镜肝切除术预后的影响[J]. 肝胆胰外科杂志, 2023, 35(8): 459-463.
[3] 史丙福, 郭全良.
中晚期肝癌64例降期转化治疗分析
[J]. 肝胆胰外科杂志, 2023, 35(8): 494-499,503.
[4] 朱坤忠, 张跃伟.
胰腺癌肝转移介入治疗的研究进展
    
[J]. 肝胆胰外科杂志, 2023, 35(8): 507-512.
[5] 范祺, 倪彦彬, 高杰, 朱继业, 李照.
原发性肝癌术后复发再次肝切除的疗效分析
[J]. 肝胆胰外科杂志, 2023, 35(7): 390-396.
[6] 陈怡, 牟弘毅, 李雪艳, 陈朝红.
基于ERAS理念的静脉血栓栓塞症预防方案在肝癌围手术期的应用
[J]. 肝胆胰外科杂志, 2023, 35(7): 397-400,406.
[7] 曹洪祥, 黄平.
肝细胞癌合并门静脉癌栓的治疗现状
[J]. 肝胆胰外科杂志, 2023, 35(4): 252-256.
[8] 周鹏宇, 李佳霖, 段清垚, 涂志坚, 雷晓华, 贺军, 陈国栋.
基于倾向性评分匹配的ERAS在原发性肝癌肝切除围手术期的应用
[J]. 肝胆胰外科杂志, 2023, 35(3): 134-139.
[9] 王进峰, 邓顺, 贺卓, 肖科, 吕品, 马铁祥, 费书珂, 刘卓, 徐彪铭, 王双, 罗建红, 欧阳永忠, 谢江波, 郑金海, 李清龙, 左朝晖.
根治性顺行模块化胰脾切除术在胰体尾部癌中的应用(多中心研究)
[J]. 肝胆胰外科杂志, 2023, 35(3): 140-145.
[10] 石银生, 方剑, 姜继华, 姜仁鸦.
TACE联合卡瑞利珠单抗及阿帕替尼治疗晚期肝细胞癌的临床研究
[J]. 肝胆胰外科杂志, 2023, 35(12): 731-735.
[11] 房达, 马良, 杜宁, 赵隶嬴, 赵乾, 高文峰, 袁春旺.
经桡动脉与股动脉行肝动脉化疗栓塞术患者接受的辐射剂量比较
[J]. 肝胆胰外科杂志, 2023, 35(12): 753-756.
[12] 欧伟森, 刘高敏, 徐继威.
循环肿瘤细胞在肝细胞癌中的临床综合应用进展
[J]. 肝胆胰外科杂志, 2023, 35(11): 701-封三.
[13] 朱洪江, 赵鹏鹏, 颜峰, 屈长征, 符延波.
人工血栓抽吸联合置管溶栓在急性非肝硬化性门静脉血栓治疗中的应用
[J]. 肝胆胰外科杂志, 2023, 35(10): 586-589.
[14] 杨俊辉, 夏景林.
肝癌TACE抵抗的预测及后续治疗研究进展
[J]. 肝胆胰外科杂志, 2023, 35(10): 629-637.
[15] 周少来, 周俭. 肝癌复发转移的防治[J]. 肝胆胰外科杂志, 2022, 34(7): 385-388.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 姚宁, 龚谋春, 方旭东, 方晓明, 姜朝晖. 肝内胆管结石128例诊治分析[J]. 肝胆胰外科杂志, 2014, 26(1): 20 -22 .
[2] 余夙慧,康牧星,孙洪伟,陈必成,周蒙滔,张启瑜. SIRS 发展在胰腺坏死、继发感染致胰腺炎病变加重中的作用[J]. 肝胆胰外科杂志, 2014, 26(1): 43 -47 .
[3] 方昌义,昝建宝,宋康颉,苗祥,何承龙,徐爱忠. 胆汁回输联合早期肠内营养对良性梗阻性黄疸患者术后血清CRP 及免疫功能的影响[J]. 肝胆胰外科杂志, 2014, 26(1): 26 -29 .
[4] 何友钊,翟年宽. 胰岛素瘤的诊断与治疗[J]. 肝胆胰外科杂志, 2014, 26(1): 1 -4 .
[5] 徐定银,郭德超,虞名旭,宋胜江. 手术切除的肝门部胆管癌生存危险因素分析[J]. 肝胆胰外科杂志, 2014, 26(1): 16 -19 .
[6] 徐家朴,张志勇. 腹腔镜胆囊切除术手术失败原因及处理[J]. 肝胆胰外科杂志, 2014, 26(2): 138 -140 .
[7] 萧岗,任培土,鲁葆春. 胰腺损伤58 例诊治体会[J]. 肝胆胰外科杂志, 2014, 26(2): 154 -156 .
[8] 龚立辉,王春,陈忠达,周建军,马周鹏. 肝内胆管乳头状瘤13例CT诊断分析[J]. 肝胆胰外科杂志, 2014, 26(4): 293 -296 .
[9] 陈亮,郭敬强,林胜璋. 大黄素对胰腺癌细胞抑癌基因P16、RASSF1A去甲基化作用研究[J]. 肝胆胰外科杂志, 2014, 26(4): 312 -316 .
[10] 邢人伟,牟永华,聂寒秋,牟一平. 腹腔镜胰体尾切除术在基层医院的初步应用[J]. 肝胆胰外科杂志, 2014, 26(3): 240 -242 .
Copyright © 2017 肝胆胰外科杂志 All Rights Reserved.
电话/传真:0577-86699363 E-mail: gdywkzz@vip.126.com
地址:浙江省温州市茶山高教园区温州医科大学图书馆A411室 邮编:325035
本系统由北京玛格泰克科技发展有限公司设计开发 技术支持:support@magtech.com.cn